BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InterValve Inc. Receives 510(k) Clearance for the V8 Aortic Valvuloplasty Balloon Catheter


4/30/2013 7:23:22 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MINNEAPOLIS--(BUSINESS WIRE)-- InterValve Inc., an early stage medical device company dedicated to advancing innovations in aortic valvuloplasty balloon catheter design, announced today that it has received 510(k) clearance to market the new V8™ Aortic Valvuloplasty Balloon Catheter in the United States.

The V8™ catheter is designed to be used in stand-alone balloon aortic valvuloplasty (BAV), and pre-dilation during transcatheter aortic valve replacement (TAVR) procedures.

“These procedures are limited today by the use of dated, conventional balloon technologies. The shape and material properties of the V8™ balloon catheter are designed to enhance both procedures through reduction in balloon movement and optimized leaflet expansion without over distention of the annulus,” said Mark Ungs, Chief Executive Officer of InterValve.

The balloon catheter features a “figure-8” shape balloon that enables the bulbs at either end of the balloon to “lock” into either side of the aortic annulus. This design has the potential to reduce the risk of balloon movement during dilatation, thereby reducing procedure and ischemic time.

The non-compliant material maintains the figure-8 shape throughout inflation which allows for leaflet hyper-extension, to create maximum valve area opening, without increasing the risk of over-stretching the annulus.

Lastly, the catheter is designed to inflate and deflate rapidly to reduce the duration of blood flow obstruction across the valve.

ABOUT BALLOON AORTIC VALVULOPLASTY (BAV) AND TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)

Calcific aortic stenosis (AS) is the most common cause of acquired valvular heart disease in the Western world with substantial morbidity and mortality. While patients can survive for years with asymptomatic AS, the prognosis following symptom onset is quite poor without intervention. Surgical aortic valve replacement is the definitive treatment for AS with universally recognized symptomatic relief and almost full restoration of age-adjusted life expectancy. However, a significant number of symptomatic AS patients forgo surgical valve replacement due to risk of complications.

In a BAV procedure a balloon catheter is placed across the valve and the leaflets are dilated with balloon inflation. This procedure can provide immediate symptom relief, but is not a long term durable solution as the leaflets tend to re-stenose.

TAVR is a new catheter based procedure that delivers a prosthetic valve via the femoral artery, but sometimes transapically. In a TAVR procedure a balloon catheter is first delivered across the native valve to pre-dilate the valve leaflets before the prosthetic valve is delivered and implanted.

Both procedures can be compromised by dilation balloon slippage during inflation, and damage to the valvular annulus by over distension.

ABOUT INTERVALVE INC.

InterValve Inc. is headquartered in Minneapolis, Minnesota. The company is dedicated to advancing innovations in aortic valvuloplasty balloon catheter design that improve procedure safety and efficacy.

Contact:

InterValve Inc.

Mr. Mark Ungs, 952-303-3539

Chief Executive Officer



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES